Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Pass-Through Payment System Needs Revision, MedPAC Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Anti-emetics illustrate the problem with the policy of providing separate payments for drugs over $50, MedPAC says. CMS is urged to use the pass-through process for all categories. MedPAC endorses CMS' proposed reimbursement change for Aranesp and Epogen in end-stage renal disease.

You may also be interested in...



Amgen EPO Claims Monitoring To Include Dosing Levels – CMS Draft Policy

Proposed revision would replace current policy of targeting physicians whose patients have average hematocrit levels over 37.5%. New policy would review erythropoietin claims with high hematocrit/hemoglobin levels and high doses.

What Justice Ginsburg’s Death Means For Pharma

A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.

Pink Sheet Podcast: COVID-19 Stresses Manufacturing, Vaccine Placebo Controls, Thorny FDA Precedents

Pink Sheet reporters and editor discuss the pandemic’s effects on non-coronavirus-related product manufacturing, US FDA efforts to ensure vaccine sponsors maintain placebo controls once a product is available, and precedents that burden the agency.

Topics

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel